Multiple Myeloma: Impact of Time to Transplant on the Outcome

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology · 1998 · 1.5K citations

Medicine, Hematology, Oncology +17

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial

Jean‐Paul Fermand, Philippe Ravaud, Sylvie Chevret et al. · Blood · 1998 · 539 citations

Medicine, Hematology, Oncology +17